Avidity Biosciences Inc RNA

NAS: RNA | ISIN: US05370A1088   15:55
25,06 USD (+1,44%)
(+1,44%)   15:55

22 april 2024 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

27 maart 2024 · Avidity Biosciences to Participate in Upcoming Investor Conferences · Persbericht

21 maart 2024 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

4 maart 2024 · Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial · Persbericht

29 februari 2024 · Avidity Biosciences Honors Rare Disease Day® · Persbericht

29 februari 2024 · Avidity Biosciences Announces Oversubscribed $400 Million Private Placement · Persbericht

28 februari 2024 · Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights · Persbericht

27 februari 2024 · Avidity Biosciences to Participate in Upcoming Investor Conferences · Persbericht

21 februari 2024 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

20 februari 2024 · Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping · Persbericht

15 februari 2024 · Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference · Persbericht

22 januari 2024 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

5 januari 2024 · Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth · Persbericht

21 december 2023 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

13 december 2023 · Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44™ Trial for Duchenne Muscular Dystrophy · Persbericht

8 november 2023 · Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights · Persbericht

23 oktober 2023 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

7 oktober 2023 · Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1 · Persbericht

26 september 2023 · Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle Society · Persbericht

25 september 2023 · Avidity Biosciences to Participate in Upcoming Investor Conferences · Persbericht

Mijn selecties